Life Science

DPS Group Completes Vibalogics Facility

Vibalogics virotherapy manufacturing facility

Boxborough, MA – DPS Group announced it has completed work on a new, 118,000sf late-phase clinical and commercial manufacturing facility at 1414 Massachusetts Avenue in Boxborough for Vibalogics, a global contract development and manufacturing organization (CDMO).

Specializing in the production of live viruses and viral vectors, Vibalogics’ GMP facility will accelerate market supply of process and analytical development, manufacturing, testing, and aseptic fill-finish services to oncolytic virus, viral vector gene therapy and vaccine drug development companies during early-to-late phase clinical trials and commercial market approval. Equipped with state-of the-art technology and ability to support a significant capacity increase, the $150 million facility is the home of Vibalogics’ global headquarters.

Through its novel therapies center of design excellence in Boston, DPS assisted Vibalogics with establishing a late phase/commercial GMP facility in the U.S. to supplement its development and early phase manufacturing facilities in Germany. DPS provided architecture and engineering design services for concept design, basis of design, detailed design, and construction administration for this project.

The facility will incorporate the use of traditional on-site construction methods alongside turnkey modular cleanrooms for the cGMP suites and associated MEP infrastructure. The site development will include office and administration space, QC/R&D laboratory space, warehousing space, GMP space, utility space, and parking to support 100 staff. Given the nature of starting materials and the substrates/agents being manufactured, these buildings will be built to meet the Center for Disease Control (CDC) guidelines for biosafety level 2 Large Scale (BSL-2LS).

The project team also included Lincoln Property Company, landlord; The Cardinal Group, pre-construction; and Germfree, modular cleanrooms.

“DPS has expertise in producing flexible and innovative cGMP sterile manufacturing facilities utilizing modern design technologies,” said Tom Hochuli, CEO at Vibalogics. “This experience made DPS a natural fit to guide us in our expansion into the U.S. market. DPS worked closely with us and other project partners to deliver a state-of-the-art manufacturing facility with maximum cost and schedule efficiency with no compromise on quality, functionality, and flexibility.”